Resistell

Resistell AG is a Swiss biotechnology start-up founded in 2018, located in the Basel region. The company specializes in ultra-rapid antibiotic susceptibility testing (AST) to combat antimicrobial resistance (AMR). Their flagship product, Phenotech, utilizes nanoscale vibrations of living bacterial cells to provide the fastest AST available, significantly reducing the time needed to determine bacterial resistance to antibiotics compared to traditional methods. Originating as a spin-off from EPFL, Resistell has developed a comprehensive technology platform that integrates hardware, software, and cloud-based analytics for life sciences applications. The company operates a BSL2 laboratory for AST testing and has a device assembly facility. Their technology has been peer-reviewed and published, highlighting its scientific validation. Resistell collaborates with academic and clinical institutions to enhance clinical decision-making and improve patient outcomes in infectious disease management. With a focus on the R&D market, they aim to expand into clinical diagnostics as they achieve further validation and regulatory approvals.

• Employees 15
• Founded 2017
• Annual Revenue $4500000
• Total Funding $15509920